Data / Drug companies / Aveva Drug Delivery Systems Inc.
Aveva Drug Delivery Systems Inc.: 23 products in the FDA NDC directory, labeler code 3215
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Aveva Drug Delivery Systems Inc. (labeler code 3215) lists 23 products in the FDA National Drug Code Directory, covering 4 finished drugs by generic name. By type: 17 prescription drugs, 6 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on November 24, 2025.
The request: Watch Aveva Drug Delivery Systems Inc. (FDA labeler code 3215): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 3215
- Products in commercial distribution
- 23
- Packages
- 28
- Finished drugs by generic name
- 4
- Prescription products
- 17
- Over the counter products
- 6
- Controlled substance products
- Schedule II 8, Schedule III 9
- Flagged as original packager
- 23 of 23 products that carry the flag
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- August 29, 2023
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 23 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 17 | 73.9% |
| Over the counter drugs | 6 | 26.1% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Fentanyl | 8 | 4 |
| Nicotine transdermal system | 6 | 10 |
| Buprenorphine | 5 | 24 |
| Buprenorphine and naloxone | 4 | 22 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Patch, extended release | 13 | 56.5% |
| Patch | 6 | 26.1% |
| Film | 4 | 17.4% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Nicotine Transdermal System | 3215-0122 | Patch | Generic drugs (ANDA) | November 24, 2025 |
| Nicotine Transdermal System | 3215-0121 | Patch | Generic drugs (ANDA) | November 24, 2025 |
| Nicotine Transdermal System | 3215-0120 | Patch | Generic drugs (ANDA) | November 24, 2025 |
| Buprenorphine and Naloxone | 3215-6522 | Film | Generic drugs (ANDA) | March 7, 2025 |
| Buprenorphine and Naloxone | 3215-6521 | Film | Generic drugs (ANDA) | March 7, 2025 |
| Fentanyl | 3215-7707 | Patch, extended release | Generic drugs (ANDA) | February 11, 2025 |
| Fentanyl | 3215-7705 | Patch, extended release | Generic drugs (ANDA) | February 10, 2025 |
| Fentanyl | 3215-7703 | Patch, extended release | Generic drugs (ANDA) | February 5, 2025 |
| Fentanyl | 3215-7701 | Patch, extended release | Generic drugs (ANDA) | January 30, 2025 |
| Fentanyl | 3215-7702 | Patch, extended release | Generic drugs (ANDA) | January 22, 2025 |
| Fentanyl | 3215-7708 | Patch, extended release | Generic drugs (ANDA) | January 6, 2025 |
| Fentanyl | 3215-7706 | Patch, extended release | Generic drugs (ANDA) | January 6, 2025 |
| Fentanyl | 3215-7704 | Patch, extended release | Generic drugs (ANDA) | January 6, 2025 |
| Nicotine Transdermal System | 3215-1203 | Patch | Generic drugs (ANDA) | June 25, 2024 |
| Nicotine Transdermal System | 3215-1202 | Patch | Generic drugs (ANDA) | June 25, 2024 |
| Nicotine Transdermal System | 3215-1201 | Patch | Generic drugs (ANDA) | June 25, 2024 |
| Buprenorphine | 3215-1525 | Patch, extended release | Generic drugs (ANDA) | November 1, 2023 |
| Buprenorphine | 3215-1524 | Patch, extended release | Generic drugs (ANDA) | November 1, 2023 |
| Buprenorphine | 3215-1523 | Patch, extended release | Generic drugs (ANDA) | November 1, 2023 |
| Buprenorphine | 3215-1522 | Patch, extended release | Generic drugs (ANDA) | November 1, 2023 |
| Buprenorphine | 3215-1521 | Patch, extended release | Generic drugs (ANDA) | November 1, 2023 |
| Buprenorphine and Naloxone | 3215-6524 | Film | Generic drugs (ANDA) | August 29, 2023 |
| Buprenorphine and Naloxone | 3215-6523 | Film | Generic drugs (ANDA) | August 29, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.